Real world characteristics and outcomes of patients with BRAFV600E-mutant metastatic colorectal cancer in Australia: The COALA project.

• DOI: 10.1200/jco.2025.43.4_suppl.70
• Publication Date: 2025-01-27T14:34:47Z
• Authors: Nadia Hitchen; Hui-Li Wong; Rachel Wong; Jeremy David Shapiro; Matthew E. Burge; Louise M. Nott; Belinda Lee; Stephanie Hui-Su Lim; Shu Fen Wong; Susan Caird; Vanessa Wong; Natalie Heather R...; Adnan Khattak; Hiren A. Mandaliya; Theresa M. Hayes; Javier Torres; Azim Jalali; Angus Campbell; Peter Gibbs; Jeanne Tie

70 Background: BRAFV600E-mutant metastatic colorectal cancer (mCRC) represents a unique molecular subset with poor prognosis and less responsiveness to chemotherapy. The BEACON CRC study demonstrated that encorafenib plus cetuximab (EC) significantly improved overall survival (OS) compared FOLFIRI in BRAF-mutant mCRC as 2 nd or 3 rd line therapy. This combination was reimbursed Australia from January 2022. Methods: We analysed data the Australian TRACC clinical registry, encompassing patients (pts) diagnosed 2009 2024 at 31 hospitals. assessed baseline demographics, uptake of EC following reimbursement efficacy analysis progression-free (PFS) OS for pts received those who did not. Pts receiving on trial were excluded. Results: Among 2,800 known BRAF mutation status, 365 (13%) mutated. mutant cohort had median age 63 years, higher rate 20-39 group than other groups (age 20-39, 25.5%; 40-59, 10%; 60+, 13.2%; P<0.001); 54.5% female, 58% right-sided tumours, 64% synchronous disease 21.7% deficient mismatch repair (dMMR). Overall, 314 (86%) tumours 2,079 (85%) wild-type (WT) 1 st treatment, 156 (43%) 1,144 (47%) WT diagnosis 17.3 months versus 34.7 (p < 0.0001). All dMMR pembrolizumab since its August 2021. 41 progressing therapy 2022,(32 pMMR, 9 dMMR), 33 (80%) subsequently treated EC, 4 (10%) not receive further treatment. start 9.6 (95% CI: 7.2-12.5) 7.1 6.4-8.6) systemic Median PFS 4.6 3.4-5.8) 3.3 2.5-5.3) treatments. Conclusions: younger 40 have high mutation, where harbour mutation. has poorer outcome despite similar proportion majority eligible Australia, outcomes consistent trial.